3i sells Betapharm to Dr Reddy's Labs

Published: 20-Feb-2006

German generic pharmaceutical company Betapharm Arzneimittel has been sold by private equity and venture capital company 3i to Dr Reddy's Laboratories in India for Euro 480m.


German generic pharmaceutical company Betapharm Arzneimittel has been sold by private equity and venture capital company 3i to Dr Reddy's Laboratories in India for Euro 480m.

Located in Augsburg, Betapharm is the fourth-largest generics company in Germany with a market share of about 3.5%. It employs around 370 people and has around 145 active ingredients in its current portfolio.

3i invested in Betapharm in March 2004 and introduced Thomas Nedtwig as a chief financial officer and managed the succession of Dr Wolfgang Niedermaier as ceo when Peter Walter retired.

An emerging global pharmaceutical company, Dr Reddy's Laboratories is headquartered in India and produces generic finished dosage forms, active pharmaceutical ingredients and biotechnology products which it markets globally.

You may also like